Artificial intelligence is poised for impact on every aspect of healthcare, healthcare systems, and clinical practice. As use cases emerge, careful analysis of ethical concerns and new legal and regulatory tools are needed. This conversation among experts will explore the ethical considerations for medical and consider current and possible legal and regulatory approaches. Panelists This…
by Mauritz Kop, Suzan Slijpen, Katie Liu, Jin-Hee Lee, Constanze Albrecht & I. Glenn Cohen I. Introduction: Harnessing Quantum and AI in Precision Medicine The convergence of artificial intelligence (AI) and quantum technology (QT) in precision medicine promises to revolutionize healthcare by enabling hyper-personalized treatment. Fundamentally, for our purposes, quantum technology leverages unique properties of…
Overview Launched in early 2018 by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and the Centre for Advanced Studies in Bioscience Innovation Law (CeBIL) at the University of Copenhagen, the Project on Precision Medicine, Artificial Intelligence, and the Law (PMAIL) will seek to better understand the frontiers of big data in health…
By Abeer Malik Imagine: Overjoyed at your pregnancy, you eagerly track every milestone, logging daily habits and symptoms into a pregnancy app. Then tragedy strikes—a miscarriage. Amidst your grief, authorities knock at your door. They’ve been monitoring your digital data and now question your behavior during pregnancy, possibly building a case against you using your…
By Rebekah Ninan This past month, California Governor Gavin Newsom signed a wave of artificial intelligence-related legislation into law. Much public debate has been focused on SB 1047, a proposal ultimately vetoed by Governor Newsom, which would have held AI companies liable for “catastrophic harms” from AI models. Comparatively little attention has been paid to…
Interviewed by William Leonard Pickard Alex Zhavoronkov, PhD, is Founder and CEO of Insilico Medicine, a leading clinical stage biotechnology company developing next-generation artificial intelligence and robotics platforms for drug discovery, with headquarters in Cambridge, MA and facilities around the world. He has invented critical technologies for the creation of novel molecular structures, and pioneered the…
By Suzan Slijpen, Mauritz Kop & I. Glenn Cohen 1. Introduction: A Fragmented AI in Healthcare Regulatory Landscape In the past few years, we have witnessed a surge in artificial intelligence-related research and diagnostics in the medical field. It is possible that in some fields of medicine in the future AI tools used in diagnostics…
Does organoid intelligence warrant recognition for the work it produces? And is that output protectible?
A rundown of the major legal questions at play in the New York Times-OpenAI lawsuit.
AI isn’t magic, but there is value in telling a magical story to non-technical stakeholders to describe how we’ll govern this transformative technology.
